This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
5 Biotech Stocks Set for Continued Rally in 2020
by Zacks Equity Research
The advance in gene therapy and RNA interference has boosted the biotech space so far in 2019. With the projected growth in the sector, here are five stocks poised to grow.
Top Ranked Momentum Stocks to Buy for December 3rd
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, December 3rd
Top Ranked Momentum Stocks to Buy for November 26th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, November 26th
Alkermes to Acquire Rodin Therapeutics, Boost CNS Pipeline
by Zacks Equity Research
Alkermes (ALKS) will acquire Rodin Therapeutics for an upfront cash payment of $100 million and up to $850 million in milestone payments.
The Zacks Analyst Blog Highlights: Coherus, Incyte, ACADIA and Celgene
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Coherus, Incyte, ACADIA and Celgene
4 Biotech Stocks That Could Keep Beating Wall Street
by Zacks Equity Research
The biotechnology industry has lagged the broader market so far this year, but these four stocks have done pretty well and should continue to do so.
Coherus BioSciences (CHRS) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Coherus BioSciences (CHRS) delivered earnings and revenue surprises of 75.00% and 19.35%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Investors Can Find Strong Stocks with our First Profit Screen
by Benjamin Rains
Today, we are utilizing our 'First Profit' stock screen to help investors find strong stocks. The idea is to search for companies that just reported their first quarterly profit within the last year...
Coherus BioSciences (CHRS) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Coherus BioSciences (CHRS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Investors Can Find Big Returns with this First Profit Screen
by Benjamin Rains
We are taking a look at our 'First Profit' stock screen today. The idea is to search for companies that just reported their first quarterly profit within the last year because these firms could prove to be big winners for investors...
Coherus BioSciences (CHRS) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Coherus BioSciences (CHRS) delivered earnings and revenue surprises of 500.00% and 2.94%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Top Ranked Momentum Stocks to Buy for July 12th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, July 12th
Coherus BioSciences (CHRS) Upgraded to Strong Buy: Here's Why
by Zacks Equity Research
Coherus BioSciences (CHRS) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Amgen (AMGN) Offers to Acquire Drug Discovery Platform
by Zacks Equity Research
Amgen (AMGN) looks to acquire Nuevolution in an all-cash deal. Nuevolution focuses on discovering small molecule drugs partnering its proprietary platform.
Coherus BioSciences (CHRS) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Coherus BioSciences (CHRS) delivered earnings and revenue surprises of 36.96% and 0.73%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Moving Average Crossover Alert: Coherus BioSciences
by Zacks Equity Research
Coherus BioSciences is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
The Zacks Analyst Blog Highlights: Incyte, Aduro Biotech, MeiraGTx and Coherus BioSciences
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Incyte, Aduro Biotech, MeiraGTx and Coherus BioSciences
5 Biotech Stocks Defying the Medicare-for-All Scare
by Swarup Gupta
Unlike the broader healthcare sector, biotech stocks have notched up strong gains year to date.
Coherus (CHRS) Catches Eye: Stock Jumps 6.9%
by Zacks Equity Research
Coherus (CHRS) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
Coherus BioSciences (CHRS): Moving Average Crossover Alert
by Zacks Equity Research
Coherus BioSciences, Inc. (CHRS) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.
GW Pharma (GWPH) Q3 Earnings: Is a Turnaround in the Cards?
by Zacks Equity Research
GW Pharma (GWPH) is expected to report its fiscal third-quarter results next week. Investors focus is expected to be on the commercialization plan for Epidiolex.
Implied Volatility Surging for Coherus BioSciences (CHRS) Stock Options
by Zacks Equity Research
Investors in Coherus BioSciences (CHRS) need to pay close attention to the stock based on moves in the options market lately.
Amgen (AMGN) Gets CHMP Nod to Expand EU Label of Neulasta
by Zacks Equity Research
Amgen (AMGN) gains positive opinion from the CHMP to update the label of Neulasta to include Neulasta Onpro Kit, an innovative delivery system.
AbbVie (ABBV) Stock Hits 52-Week High: More Room to Run?
by Zacks Equity Research
AbbVie Inc. (ABBV) shares hit a 52-week high of $71.12 on Friday before eventually closing at $71.05.
Coherus Stock Plummets as FDA Rejects Neulasta Biosimilar
by Zacks Equity Research
Coherus Biosciences, Inc. (CHRS) shares declined nearly 24% in yesterday's trading as it announced that it has received a complete response letter (CRL) from the FDA for its biosimilar version of Amgen Inc's (AMGN) blockbuster drug, Neulasta.